title: Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO survey.
abstract: BACKGROUND
  Randomized studies have shown a reduction in cardiovascular events associated with low doses of statin among hypertensive patients at only moderate cardiovascular risk. The hypothesis of the present study was that statin therapy initiated during hospitalization could improve the long-term outcome after acute myocardial infarction (MI) in hypertensive patients.
  
  
  METHODS
  From the French regional obserRvatoire des Infarctus de Côte d'Or (RICO) survey, 1076 patients with a history of hypertension, surviving acute MI were included. Patients on statin therapy initiated before their hospitalization were excluded from the study. Patients were categorized into two groups based on whether or not statin treatment was initiated during the hospital stay.
  
  
  RESULTS
  Patients in the statin group were younger (70 years [range, 58 to 77 years] v 75 years [range, 65 to 82 years], P < .001) and were more likely to have hypercholesterolemia (42% v 28 %, P < .001). No differences were observed between the two groups for LDL-cholesterol levels on admission. At 1-year follow-up, cardiovascular mortality and rehospitalization for heart failure were lower in the statin group (respectively, 5% v 15%, P < .001; 5% v 7%, P < .001). Multivariate analysis showed that statin therapy was associated with decreased mortality (hazard ratio [95% confidence interval; CI]: 0.58 [0.32-0.98], P = .035) independently of either hypercholesterolemia, the use of beta-blockers, angiotensin-converting enzyme inhibitors, or diuretics, but not with a decreased incidence of heart failure (hazard ratio [95% CI]: 0.88 [0.55-1.23], P = .152).
  
  
  CONCLUSIONS
  In this observational study, the long-term benefits of statin therapy initiated in-hospital in hypertensive patients after acute MI was demonstrated. These findings may have implications for treatment optimization of hypertensive patients in secondary prevention.
authors.affiliation: Laboratoire de Physiopathologie et Pharmacologie Cardio-vasculaires Expérimentales, IFR Santé-STIC, Facultés de Médecine et de Pharmacie, Dijon, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Sicard
authors.forename: Marianne
authors.initials: M
authors.lastname: Zeller
authors.forename: Gilles
authors.initials: G
authors.lastname: Dentan
authors.forename: Yves
authors.initials: Y
authors.lastname: Laurent
authors.forename: Claude
authors.initials: C
authors.lastname: Touzery
authors.forename: Isabelle
authors.initials: I
authors.lastname: L'huillier
authors.forename: Luc
authors.initials: L
authors.lastname: Janin-Manificat
authors.forename: Luc
authors.initials: L
authors.lastname: Lorgis
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Beer
authors.forename: Hamib
authors.initials: H
authors.lastname: Makki
authors.forename: Luc
authors.initials: L
authors.lastname: Rochette
authors.forename: Yves
authors.initials: Y
authors.lastname: Cottin
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000378:metabolism; D003625:Data Collection; D016208:Databases, Factual; D005260:Female; D005602:France / Q000453:epidemiology; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006973:Hypertension / Q000150:complications*; D008055:Lipids / Q000097:blood; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality*; D016017:Odds Ratio; D012307:Risk Factors; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D002097:C-Reactive Protein